Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities, and in adolescents aged 12 years and older with obesity
En este contexto, es destacable que, igual que no hay evidencia de que funcionen para adelgazar, tampoco conllevan efectos secundarios
1,2 Victoza is administered once daily
GLP-1 Drugs Compared: Ozempic, Wegovy, Trulicity, Victoza, and Mounjaro From weekly shots that target blood sugar to higher-dose pens approved purely for weight loss, todays GLP-1 medications arent interchangeable
Time-course experiments using phospho-specific antibodies track enhanced FAK activation kinetics under combined treatment conditions